IDH-mutant astrocytomas are now graded as WHO grade II, III, or IV (Louis et al., 2021) and also harbor ATRX and TP53 mutations (Marker et al., 2021). The gene discussed is ATRX; the disease is astrocytoma (excluding glioblastoma).